A Study to Assess the Effects of Bempedoic Acid in Patients with or at high risk for Cardiovascular Disease

Status: open

A Randomized, Double-Blind, Placebo-Controlled study to Assess the Effects of Bempedoic Acid (ETC-1002) on the occurrence of Major Cardiovascular Events in Patients with, or at High Risk for Cardiovascular Disease who are Statin-Intolerant

Treatment for Cardiovascular Disease

Contact Us Or call 251-471-7027


The primary objective is to evaluate whether administration of bempedoic acid 180 mg/day versus placebo reduces the risk of MACE in patients with, or at high risk for, CVD who are statin intolerant. This will be assessed with a composite primary efficacy endpoint that includes time to first occurrence of CV death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina, or coronary revascularization.


This trial is sponsored by Esperion Therapeutics, Inc..

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.